MANEVeradermics, Incvs its industry peers
A metric-by-metric comparison of Veradermics, Inc against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MANEEsta | $4.4B#6 | — | 11.2x#12 | — | — | -164.3%#15 | — | -17.9%#8 | — | — | — | — |
| ORKA | $5.7B#2 | — | 11.7x#13 | — | — | -25.9%#10 | — | -21.7%#10 | — | — | 593.2%#2 | — |
| ERAS | $5.6B#3 | — | 14.2x#14 | — | — | 23.0%#5 | — | -31.6%#14 | — | — | 1175.9%#1 | — |
| TVTX | $5.2B#4 | — | 52.8x#16 | 10.6x#4 | 110.5%#2 | 92.1%#1 | -12.8%#4 | -25.9%#12 | -94.7%#6 | — | 263.2%#6 | — |
| DNTH | $5.8B#1 | — | 4.8x#4 | 2860.0x#8 | -67.3%#8 | -91.1%#14 | -8739.3%#8 | -13.5%#7 | — | — | 415.5%#3 | — |
| DYN | $4.6B#5 | — | 6.6x#5 | — | — | -40.6%#12 | — | -0.0%#3 | -1301.5%#7 | — | 150.7%#10 | — |
| ACAD | $4.4B#7 | 11.5x#1 | 3.5x#2 | 4.1x#2 | 11.9%#5 | 73.0%#3 | 9.8%#2 | 31.3%#1 | 10.9%#1 | — | 6.9%#14 | — |
| EWTX | $4.2B#8 | — | 8.5x#9 | — | — | -25.4%#9 | — | -0.0%#4 | -41.6%#4 | — | 171.8%#9 | — |
| TNGX | $3.9B#9 | — | 9.9x#11 | 62.2x#6 | 48.3%#4 | 22.0%#6 | -178.4%#6 | -26.0%#13 | — | — | 344.7%#5 | — |
| VKTX | $3.7B#10 | — | 9.1x#10 | — | — | -227.1%#16 | — | -88.1%#16 | — | — | -2.1%#15 | — |
| OGN | $3.6B#11 | 17.4x#2 | 3.5x#3 | 0.6x#1 | -2.9%#6 | -78.4%#13 | 14.9%#1 | 18.6%#2 | 4.9%#2 | 5#1 | 43.0%#13 | 2.5%#1 |
| RCUS | $3.5B#12 | — | 6.6x#6 | 105.2x#7 | -35.3%#7 | -24.7%#8 | -1169.7%#7 | -67.4%#15 | -91.3%#5 | — | 202.4%#7 | — |
| ARQT | $3.3B#13 | — | 17.5x#15 | 8.8x#3 | 91.3%#3 | 88.5%#2 | -3.3%#3 | -8.5%#5 | -4.6%#3 | — | 81.6%#11 | — |
| ELVN | $3.3B#14 | — | 7.2x#8 | — | — | -16.5%#7 | — | -22.9%#11 | — | — | 186.3%#8 | — |
| IDYA | $3.1B#15 | — | 3.3x#1 | 14.3x#5 | 3024.4%#1 | 58.6%#4 | -72.8%#5 | -12.1%#6 | — | — | 46.2%#12 | — |
| MBX | $3.1B#16 | — | 7.1x#7 | — | — | -40.5%#11 | — | -19.9%#9 | — | — | 395.2%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-08-01.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice